Aldeyra Therapeutics
ALDX
105 hedge funds and large institutions have $125M invested in Aldeyra Therapeutics in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 24 increasing their positions, 47 reducing their positions, and 36 closing their positions.
4.03% less ownership
Funds ownership: 64.46% → 60.43% (-4%)
13% less funds holding
Funds holding: 120 → 105 (-15)
14% less call options, than puts
Call options by funds: $383K | Put options by funds: $446K
42% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 36
49% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 47
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less capital invested
Capital invested by funds: $252M → $125M (-$127M)
Top Buyers
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$7.54M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$3.94M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.28M |
| 4 |
Morgan Stanley
New York
|
+$1.82M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.2M |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$8.51M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$7.54M |
| 3 |
State Street
Boston,
Massachusetts
|
-$6.69M |
| 4 |
Rafferty Asset Management
New York
|
-$1.79M |
| 5 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$869K |
ALDX Hedge Fund Activity: Q4 2023 in Review
105 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2023, worth a combined $125M — down 50% from $252M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ALDX and 21 opened new positions — a net loss of 15 holders — while 47 trimmed existing stakes and 24 added.
The largest buyer was Knoll Capital Management, adding an estimated $7.54M. The largest seller was Perceptive Advisors, cutting an estimated $8.51M.
- 105 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2023, down from 120 in Q3 2023.
- Funds reported $125M of Aldeyra Therapeutics stock for Q4 2023, down 50% quarter-over-quarter.
- 21 funds opened new Aldeyra Therapeutics positions in Q4 2023 and 36 closed out, a net change of -15 holders.
- The largest Aldeyra Therapeutics buyer in Q4 2023 was Knoll Capital Management, an estimated $7.54M added.
- The largest Aldeyra Therapeutics seller in Q4 2023 was Perceptive Advisors, an estimated $8.51M sold.
Based on aggregated 13F filings for Q4 2023.